MedTrace Logo

Association of Serum Eotaxin Levels and Markers of Myocardiac Injury in Hemodialysis Patients

NCT06211244 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 291

Last updated 2025-06-06

No results posted yet for this study

Summary

Background:

Cardiovascular disease (CVD) is one of the leading causes of morbidity and mortality among dialysis patients. Eotaxin-1(also known as Eotaxin and CCL11), an eosinophil-specific chemoattractant that plays a role in a variety of pathologic conditions including allergy, coronary heart disease, and inflammatory bowel disease. CCL11 has been shown to be overexpressed in human atherosclerotic lesions. Moreover, eotaxin-1 levels are higher in non-uremic coronary artery disease patients than in healthy individuals.

Methods:

The study will enrolled 400 hemodialysis patients. Patients are diagnosed with coronary artery disease based on clinical presentation and confirmed by angiography. Serum eotaxin-1 and 8-isoprostane levels are determined by enzyme-linked immunosorbent assay (ELISA). High-sensitivity cTnI immunoassays and albumin redox state by high-performance liquid chromatography are used for measurements.

Aim:

In this study, we aimed to determine the eotaxin-1 concentrations of patients with coronary artery disease and to investigate the role of eotaxin-1 and markers of myocardial injury.

Conditions

Sponsors & Collaborators

  • Tungs' Taichung Metroharbour Hospital

    lead OTHER

Principal Investigators

  • Paik Seong Lim, PhD · Tungs' Taichung Metroharbour Hospital

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-02
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06211244 on ClinicalTrials.gov